Logo image of EPIX

ESSA PHARMA INC (EPIX) Stock Fundamental Analysis

NASDAQ:EPIX - Nasdaq - CA29668H7085 - Common Stock - Currency: USD

1.72  -0.03 (-1.71%)

After market: 1.7002 -0.02 (-1.15%)

Fundamental Rating

3

EPIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. EPIX has a great financial health rating, but its profitability evaluates not so good. EPIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPIX has reported negative net income.
In the past year EPIX has reported a negative cash flow from operations.
In the past 5 years EPIX always reported negative net income.
In the past 5 years EPIX always reported negative operating cash flow.
EPIX Yearly Net Income VS EBIT VS OCF VS FCFEPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of EPIX (-25.37%) is better than 72.82% of its industry peers.
EPIX has a better Return On Equity (-26.19%) than 80.82% of its industry peers.
Industry RankSector Rank
ROA -25.37%
ROE -26.19%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPIX Yearly ROA, ROE, ROICEPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPIX Yearly Profit, Operating, Gross MarginsEPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

There is no outstanding debt for EPIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPIX Yearly Shares OutstandingEPIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EPIX Yearly Total Debt VS Total AssetsEPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 9.55 indicates that EPIX is not in any danger for bankruptcy at the moment.
EPIX has a Altman-Z score of 9.55. This is amongst the best in the industry. EPIX outperforms 87.21% of its industry peers.
EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.55
ROIC/WACCN/A
WACCN/A
EPIX Yearly LT Debt VS Equity VS FCFEPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 33.12 indicates that EPIX has no problem at all paying its short term obligations.
EPIX has a better Current ratio (33.12) than 97.69% of its industry peers.
A Quick Ratio of 33.12 indicates that EPIX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 33.12, EPIX belongs to the top of the industry, outperforming 97.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 33.12
Quick Ratio 33.12
EPIX Yearly Current Assets VS Current LiabilitesEPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

EPIX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.95%.
EPS 1Y (TTM)-16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EPIX will show a very strong growth in Earnings Per Share. The EPS will grow by 73.51% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.1%
EPS Next 2Y22.23%
EPS Next 3Y37.47%
EPS Next 5Y73.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPIX Yearly Revenue VS EstimatesEPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
EPIX Yearly EPS VS EstimatesEPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPIX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPIX Price Earnings VS Forward Price EarningsEPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPIX Per share dataEPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

EPIX's earnings are expected to grow with 37.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.23%
EPS Next 3Y37.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESSA PHARMA INC

NASDAQ:EPIX (2/21/2025, 8:15:54 PM)

After market: 1.7002 -0.02 (-1.15%)

1.72

-0.03 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners70.94%
Inst Owner Change-87.96%
Ins Owners2.24%
Ins Owner Change-588.69%
Market Cap76.35M
Analysts48.89
Price Target1.89 (9.88%)
Short Float %1.47%
Short Ratio1.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.06%
Min EPS beat(2)-3.49%
Max EPS beat(2)29.61%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-4.3%
Max EPS beat(4)36.23%
EPS beat(8)6
Avg EPS beat(8)20.06%
EPS beat(12)10
Avg EPS beat(12)23.19%
EPS beat(16)13
Avg EPS beat(16)16.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-84.88%
PT rev (3m)-84.88%
EPS NQ rev (1m)-4.35%
EPS NQ rev (3m)75.51%
EPS NY rev (1m)4.27%
EPS NY rev (3m)4.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0
BVpS2.68
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.37%
ROE -26.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.12
Quick Ratio 33.12
Altman-Z 9.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
EPS Next Y23.1%
EPS Next 2Y22.23%
EPS Next 3Y37.47%
EPS Next 5Y73.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.63%
OCF growth 3YN/A
OCF growth 5YN/A